ELTX ANGION BIOMEDICA CORP

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.

A live webcast of the presentation will be accessible under “” in the Investors section of Elicio’s and will be available on-demand for 90 days following the event.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media Contact

Kristin Politi

LifeSci Communications



646-876-4783

Investor Relations Contact

Heather DiVecchia

Elicio Therapeutics



857-209-0153



EN
05/02/2024

Underlying

ELTXANGION BIOMEDICA CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANGION BIOMEDICA CORP

 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-2...

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacyELI-002 induced both CD4+...

August 12, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and ...

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival (“DFS”) expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, I...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Announces Positive Recommendation by IDMC to Conti...

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis The AMPLIFY-7P study of ELI-002 7P successfully passes event-driven interim analysis for efficacy, futility, and safety by the IDMC The Company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy Final disease-free survival analysis is anticipated to occur in Q4 2025Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3...

August 5, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Disc...

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS (“mKRAS”) ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Secures $10 Million in Financing

Elicio Therapeutics Secures $10 Million in Financing Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”) (the “Note Financing”). The proceeds f...

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch